Table 2 Ongoing clinical trials for pancreatic cancer treatment

From: The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Condition or disease	Intervention/treatment	Target	ClinicalTrials.gov identifier	Phase	Status and results	Reference
Metastatic PDAC	Mesenchymal stromal cell-derived exosomes with KRAS^G12D siRNA	KRAS	NCT03608631	1	Not yet recruiting	³⁶⁵
NTRK fusion-positive solid tumors	Entrectinbi	NTRK inhibitor	NCT02568267	2	Recruiting	³⁶⁶
NTRK fusion-positive solid tumors	Larotrectinib	NTRK inhibitor	NCT02576431	2	Recruiting	³⁶⁷
Advanced solid tumors	Ceritinib	ALK inhibitor	NCT02227940	1	Completed
BRCA-mutated metastatic pancreatic cancer	Olaparib maintenance	PARP inhibitor	NCT02184195	3	Completed, ORR and PFS improved	¹⁴
Advanced PDAC	Nivolumab with cabiralizumab with or without chemotherapy	Anti-PD-1 antibodies and CSF-1R antibodies	NCT03336216	2	Active, not recruiting
Metastatic pancreatic cancer	Pembrolizumab and BL-8040	Anti-PD-1 antibodies and CXCR4 antagonist	NCT02907099	2	Active, not recruiting
Non-colorectal MSI-H/dMMR-deficient cancer	Pembrolizumab	anti-PD-1 antibodies	NCT02628067	2	Completed, ORR 18.2%, CR 4.5%, and PR 13.6% for PDAC	³⁷³
Metastatic PDAC	Durvalumab with or without tremelimumab	Anti-PD-L1 antibodies, anti-CTLA-4 antibodies	NCT02558894	2	Completed, tolerated, ORR 3.1% for combination therapy
Locally advanced or metastatic RAS-mutant solid tumors	Avelumab, binimetinib, and talazoparib, second line	Anti-PD-L1 antibodies, MEK inhibitor, PARP inhibitor	NCT03637491	2	Recruiting
Metastatic PDAC	Devimistat with mFOLFIRINOX	Tricarboxylic acid cycle modulation	NCT03504423	3	Recruiting	³⁷⁸
Advanced or metastatic PDAC	Hydroxychloroquine with gemcitabine/nab-paclitaxel	Autophagy inhibitor	NCT01506973	1/2	Active, not recruiting
Advanced or metastatic PDAC	Hydroxychloroquine and trametinib	Autophagy inhibitor, MEK inhibitor	NCT03825289	1	Recruiting
Advanced or metastatic PDAC	Paclitaxel liposome and S-1	–	NCT04217096		Active, not recruiting
Stage IV untreated PDAC	PEGPH20 based on nab-paclitaxel and gemcitabine	Recombinant human hyaluronidase	NCT01839487	2	Completed, improved PFS and ORR	³⁷⁵
Previously treated Hyaluronan high metastatic PDAC	PEGPH20 with pembrolizumab	Recombinant human hyaluronidase, anti-PD-1 antibodies	NCT03634332	2	Recruiting
Advanced solid tumors	Defactinib with pembrolizumab	FAK inhibitor, PD-1 antagonist	NCT02758587	1/2	Recruiting
PDAC	GSK2256098 with trametinib	FAK inhibitor, MEK inhibitor	NCT02428270	1	Active, not recruiting
Unresectable pancreatic cancer	Pamrevlumab based on gemcitabine and nab-paclitaxel	CTGF antagonism	NCT02210559	1/2	Active, not recruiting
Pancreatic cancer	CAR T cells, second line		NCT03323944	1	Active, not recruiting
Metastatic pancreatic cancer	Paclitaxel and gemcitabine plus or without napabucasin	STAT3 and cancer cell stemness inhibitor	NCT03721744	3	Recruiting
Metastatic PDAC	Napabucasin plus nab-paclitaxel with gemcitabine	Cancer stemness inhibitor	NCT02993731	3	Active, not recruiting

CR complete response, ORR objective response rate, PARP poly-(ADP-ribose) polymerase, PDAC pancreatic ductal adenocarcinomas, PFS progression-free survival, PR partial response

Back to article page

Table 2 Ongoing clinical trials for pancreatic cancer treatment

Search

Quick links